TABLE 1.

COVID‐19‐related findings in the 63 patients with COVID‐19 and GBS

Clinical findings (patients, n = 63)	% (patients, n)
Nasopharyngeal swab positivity	93.7% (59)
Anti‐SARS‐CoV‐2 positivity	6.3% (4)
Interstitial pneumonia on chest X‐ray or chest computed tomography	96.8% (61)
COVID symptoms	Fever 84.1% (53) Cough 79.4% (50) Dyspnea 68.3% (43) Dysgeusia 31.7% (20) Anosmia 30.2% (19) Gastrointestinal symptoms 19.0% (12) Asymptomatic 1.6% (1)
PaO2 at hospitalization (mean ± SD)	57.12 ± 25.3 mmHg
Oxygen therapy	84.1% (53)
Non‐invasive ventilation	52.4% (33)
Invasive ventilation	27% (17)
COVID therapy	Antibiotic therapy 84.1% (53) Prophylactic dose heparin therapy 68.3% (43) Steroid therapy 58.7% (37) Hydroxychloroquine 41.3% (26) Antiviral therapy 27% (17) Heparin with an anticoagulant dosage 23.8% (15) Tocilizumab 11.1% (7)
Admission to ICU	49.2% (31)
Mean ICU hospitalization duration	26.42 ± 11.34 days
SOFA score at hospitalization (mean ± SD)	3.87 ± 3.68
SOFA score at discharge (mean ± SD)	2.69 ± 2.63
Interval from onset of COVID‐19 symptoms and GBS symptoms (mean ± SD)	18.02 ± 12.01 days

Abbreviations: COVID, coronavirus disease; GBS, Guillain–Barré syndrome; ICU, intensive care unit; SOFA, sequential organ failure assessment score.